Monoclonal Antibodies Market By Application 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Monoclonal Antibodies Market
Monoclonal Antibodies Market: By Application [Oncology, Autoimmune and inflammatory diseases, Respiratory diseases and Ophthalmology] & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
Report Code : HCR 0320
Published On: 27 January, 2016   Updated On: 27 January, 2016

  • Report Description
  • Table of Contents
  • Customization Options
Antibodies are increasingly becoming the preferred choice to treat several disorders such as respiratory diseases, oncology, and inflammatory diseases. The rising application of these antibodies in drug development increases revenue generation in the mAbs market, contributing to the overall market growth. Globally, technological enhancements and huge R&D in genomic studies, continuous improvement and innovation in Monoclonal Antibodies technologies and growing population are the prime growth drivers of Monoclonal Antibodies market. In addition, Increase in adoption of Monoclonal Antibodies in emerging economies such as China, India and others, will create new opportunities for moloclonal antibodies market. However, higher cost of the research and development, and complex government approval processes are the key restraints for moloclonal antibodies market.

 Monoclonal Antibodies Market

Globally, Asia Pacific will be the fastest-growing region in the mAbs market and is likely to grow. Much of the region’s growth can be attributed to the rising occurrence of diseases and healthcare investments provided by the respective governments and increased out-of-pocket expenditure by individuals. Moreover, the rising number of initiatives undertaken by major vendors to assist patients in the Asia Pacific countries and recent launches of new products are significant contributors to the high sales of sales mAbs in this region.

This report identifies the global Monoclonal Antibodies market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global Monoclonal Antibodies market.

This report segments global Monoclonal Antibodies market on the basis of application, and regional market as follows:
  • Global Monoclonal Antibodies Market By Application: Oncology, Autoimmune and inflammatory diseases, Respiratory diseases and Ophthalmology and Others
  • This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico

This report identifies all the major companies operating in the global Monoclonal Antibodies market. Some of the major companies’ profiles in detail are as follows:
  • AbGenomics
  • ADC Therapeutics
  • Agensys
  • Alexion Pharmaceuticals
  • ALMAC Group
1. Monoclonal Antibodies – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Monoclonal Antibodies – Market Forces
   4.1. Drivers
      4.1.1. Technological enhancements and huge R&D in genomic studies
      4.1.2. Continuous improvement and innovation in Monoclonal Antibodies technologies
      4.1.3. Growing Population
   4.2. Restrains
      4.2.1 High developmental costs
   4.3. Opportunities
      4.3.1 Emerging Economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Monoclonal Antibodies – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Monoclonal Antibodies Market, By Application
   6.1. Oncology
   6.2. Autoimmune and inflammatory diseases
   6.3. Respiratory diseases
   6.4. Ophthalmology UV-Visible (Photodiode Array, Handheld)
   6.5. Others
7. Monoclonal Antibodies Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Monoclonal Antibodies – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   9.1. AbGenomics
   9.2. ADC Therapeutics
   9.3. Agensys
   9.4. Alexion Pharmaceuticals
   9.5. ALMAC Group
   9.6. Ambrx
   9.7. Astellas Pharma
   9.8. AstraZeneca
   9.9. Bayer HealthCare
   9.10. Biogen
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix

   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of expert Insights
   10.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll